Advertising

Johnson & Johnson

JNJ-N

NYSE:JNJ

171.79
1.81 (1.06%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
Chart
BUY
BUY
July 14, 2021

JNJ vs. PG Valuation of 16-17x earnings is cheaper than PG. A healthcare company: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. Medical device side should do well post-Covid. Dividends similar in the 2.5% range.

Show full opinionHide full opinion

JNJ vs. PG Valuation of 16-17x earnings is cheaper than PG. A healthcare company: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. Medical device side should do well post-Covid. Dividends similar in the 2.5% range.

Gordon Reid
Price
$170.185
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
June 28, 2021
It has been a great long term stock. He would own it if it were a little cheaper. They are in a good sector. The entry point is too expensive, otherwise he would like to own it.
Show full opinionHide full opinion
It has been a great long term stock. He would own it if it were a little cheaper. They are in a good sector. The entry point is too expensive, otherwise he would like to own it.
Lorne Steinberg
Price
$164.020
Owned
No
BUY
BUY
June 24, 2021

Doesn't own, but likes it. Steady, strong technical chart on the upswing. 17x earnings for a 9% growth rate. Diversified products, strong management. Great for cashflow and long-term growth. He prefers Pfizer and ABBV. See his Top Picks today. Yield is 2.6%.

Show full opinionHide full opinion

Doesn't own, but likes it. Steady, strong technical chart on the upswing. 17x earnings for a 9% growth rate. Diversified products, strong management. Great for cashflow and long-term growth. He prefers Pfizer and ABBV. See his Top Picks today. Yield is 2.6%.

Stan Wong
Price
$163.050
Owned
No
BUY
BUY
June 17, 2021
Great company because of its diversified businesses of pharma, medical devices, and personal care products. Great dividend yield, increased for 54 years in a row. Great free cashflow growth.
Show full opinionHide full opinion
Great company because of its diversified businesses of pharma, medical devices, and personal care products. Great dividend yield, increased for 54 years in a row. Great free cashflow growth.
Paul Harris, CFA
Price
$164.710
Owned
Yes
BUY
BUY
June 14, 2021
It is a stable holding, which has in fact been a headwind. It will probably ebb and flow. There are some company specific catalysts there as well, though.
Show full opinionHide full opinion
It is a stable holding, which has in fact been a headwind. It will probably ebb and flow. There are some company specific catalysts there as well, though.
Jennifer Radman
Price
$165.370
Owned
Yes
BUY
BUY
June 14, 2021
It's a teflon stock with a good drug pipeline. This will go up no matter what.
Show full opinionHide full opinion
It's a teflon stock with a good drug pipeline. This will go up no matter what.
Jim Cramer - Mad Money
Price
$165.370
Owned
Unknown
HOLD
HOLD
May 19, 2021

JNJ vs. ABT Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

Show full opinionHide full opinion

JNJ vs. ABT Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

Stan Wong
Price
$169.430
Owned
Unknown
BUY
BUY
May 14, 2021

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

Show full opinionHide full opinion

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

JoAnne Feeney
Price
$170.520
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
May 12, 2021
(A Top Pick May 11/20, Up 16%) Great dividend yield, and keeps increasing. Trades at 18x earnings. Likes its 3 divisions of pharma, medical devices, and personal care. This smooths out the volatility and revenue. Cashflow machine.
Show full opinionHide full opinion
(A Top Pick May 11/20, Up 16%) Great dividend yield, and keeps increasing. Trades at 18x earnings. Likes its 3 divisions of pharma, medical devices, and personal care. This smooths out the volatility and revenue. Cashflow machine.
Paul Harris, CFA
Price
$168.870
Owned
Yes
BUY
BUY
April 16, 2021
They report Tuesday. The CDC, he feels, has unfairly punished JNJ over its Covid vaccine. He expects JNJ to release a strong quarter and pipeline of drugs.
Show full opinionHide full opinion
They report Tuesday. The CDC, he feels, has unfairly punished JNJ over its Covid vaccine. He expects JNJ to release a strong quarter and pipeline of drugs.
Jim Cramer - Mad Money
Price
$162.240
Owned
Unknown
DON'T BUY
DON'T BUY
April 13, 2021

This morning the news said that distribution has been halted in the US, so the stock is declining today. Like Pfzier, JNJ is seeing a one-time bump because of their vaccine. JNJ is struggling in their consumer business as consumers move to generic drugs, not branded. Also, litigation remains a cloud, referring to asbestos in its Baby Powder. There are other opportunities in healthcare, like Anthem, the insurer, or retailer CVS, or Abbvie trading at a reasonable PE and offers good growth.

Show full opinionHide full opinion

This morning the news said that distribution has been halted in the US, so the stock is declining today. Like Pfzier, JNJ is seeing a one-time bump because of their vaccine. JNJ is struggling in their consumer business as consumers move to generic drugs, not branded. Also, litigation remains a cloud, referring to asbestos in its Baby Powder. There are other opportunities in healthcare, like Anthem, the insurer, or retailer CVS, or Abbvie trading at a reasonable PE and offers good growth.

Gordon Reid
Price
$159.425
Owned
No
PAST TOP PICK
PAST TOP PICK
April 6, 2021
(A Top Pick Mar 12/20, Up 34%) A great company. Pharma, medical technology and consumer products are its three divisions, so if one lags, the others pick up the slack. Has great cash flow and pays an increasing yield. They came out with a Covid vaccine quickly. Developing drugs is a risk, because it depends on FDA approval, but JNJ operates three divisions to spread overall risk. He likes that, unlike pure pharma which depend on their drug pipeline.
Show full opinionHide full opinion
(A Top Pick Mar 12/20, Up 34%) A great company. Pharma, medical technology and consumer products are its three divisions, so if one lags, the others pick up the slack. Has great cash flow and pays an increasing yield. They came out with a Covid vaccine quickly. Developing drugs is a risk, because it depends on FDA approval, but JNJ operates three divisions to spread overall risk. He likes that, unlike pure pharma which depend on their drug pipeline.
Paul Harris, CFA
Price
$163.430
Owned
Yes
WATCH
WATCH
March 24, 2021
Has many brands that are billion dollar platforms. Consistent growth over last 25 years. High quality. Good positioning in consumer healthcare, pharma, and medical devices. On his focus list.
Show full opinionHide full opinion
Has many brands that are billion dollar platforms. Consistent growth over last 25 years. High quality. Good positioning in consumer healthcare, pharma, and medical devices. On his focus list.
TOP PICK
TOP PICK
March 16, 2021
It's done relatively year. Their pharma pipeline remains strong and accounts for nearly half their revenues. The medical devices business is a recovery play as elective surgeries will see a ramp up after delays from Covid. JNJ will grow earnings in double-digits for the next couple years. It trades at a reasonable 17x PE. Has a strong balance sheet, and has raised its dividend for 58 straight years (now 2.5%). She likes healthcare long term. JNJ won't make much money off their vaccine, but their pharma pipeline is solid. (Analysts’ price target is $183.68)
Show full opinionHide full opinion
It's done relatively year. Their pharma pipeline remains strong and accounts for nearly half their revenues. The medical devices business is a recovery play as elective surgeries will see a ramp up after delays from Covid. JNJ will grow earnings in double-digits for the next couple years. It trades at a reasonable 17x PE. Has a strong balance sheet, and has raised its dividend for 58 straight years (now 2.5%). She likes healthcare long term. JNJ won't make much money off their vaccine, but their pharma pipeline is solid. (Analysts’ price target is $183.68)
Christine Poole
Price
$161.370
Owned
Yes
BUY
BUY
March 15, 2021
They boast a long track record of paying dividends. They produced an approved one-shot Covid vaccine. JNJ has a good history of doing right for its shareholders. Great balance sheet and has a history of developing new job. JNJ won't make a lot of money off its Covid vaccine. It has the best balance sheet of any large company in the U.S.
Show full opinionHide full opinion
They boast a long track record of paying dividends. They produced an approved one-shot Covid vaccine. JNJ has a good history of doing right for its shareholders. Great balance sheet and has a history of developing new job. JNJ won't make a lot of money off its Covid vaccine. It has the best balance sheet of any large company in the U.S.
Jim Cramer - Mad Money
Price
$160.420
Owned
Unknown
Showing 1 to 15 of 491 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 23

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 8

Total Signals / Votes : 34

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 34 stock analysts published opinions about JNJ-N. 23 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by Gordon Reid on 2021-07-14. Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

34 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2021-07-23, Johnson & Johnson (JNJ-N) stock closed at a price of $171.79.